(NASDAQ: TARS) Tarsus Pharmaceuticals's forecast annual revenue growth rate of 27.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Tarsus Pharmaceuticals's revenue in 2026 is $535,079,000.On average, 11 Wall Street analysts forecast TARS's revenue for 2026 to be $30,471,288,722, with the lowest TARS revenue forecast at $28,692,248,018, and the highest TARS revenue forecast at $31,803,310,493. On average, 9 Wall Street analysts forecast TARS's revenue for 2027 to be $39,676,264,750, with the lowest TARS revenue forecast at $35,838,957,847, and the highest TARS revenue forecast at $44,658,869,442.
In 2028, TARS is forecast to generate $47,025,187,187 in revenue, with the lowest revenue forecast at $40,334,531,323 and the highest revenue forecast at $57,264,889,429.